Molecular Modeling Design Strategy on Novel Drugs for HIV-1 Tat/TAR Complex

2000 ◽  
Vol 28 (5) ◽  
pp. A436-A436
Author(s):  
L. P. Gomes ◽  
L. J. O. Figueiredo ◽  
O. A. C. Antunes
Keyword(s):  
Molecular Modeling ◽  
Design Strategy ◽  
Novel Drugs ◽  
Hiv 1

scholarly journals Molecular modeling and in vitro activity of an HIV-1-encoded glutathione peroxidase

2000 ◽  
Vol 97 (12) ◽  
pp. 6356-6361 ◽  
Author(s):  
L. Zhao ◽  
A. G. Cox ◽  
J. A. Ruzicka ◽  
A. A. Bhat ◽  
W. Zhang ◽  
...  
Keyword(s):  
Molecular Modeling ◽  
Glutathione Peroxidase ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Hiv 1

scholarly journals Novel drugs and treatment strategies for HIV-1

2012 ◽  
Vol 10 (11) ◽  
pp. 1265-1267 ◽  
Author(s):  
Christopher James Kevin Ward
Keyword(s):  
Treatment Strategies ◽  
Novel Drugs ◽  
Hiv 1

NMR and molecular modeling characterization of HIV-1 protease inhibitors: Difunctional enols of N-protected phenylalanine

Tetrahedron ◽  
1997 ◽  
Vol 53 (12) ◽  
pp. 4231-4238 ◽  
Author(s):  
Yvan Boulanger ◽  
Alain Larocque ◽  
Abdesslem Khiat ◽  
François Deschamps ◽  
Gilles Sauvé
Keyword(s):  
Molecular Modeling ◽  
Protease Inhibitors ◽  
Hiv 1

Molecular modeling studies of N-substituted pyrrole derivatives—Potential HIV-1 gp41 inhibitors

2008 ◽  
Vol 16 (6) ◽  
pp. 3039-3048 ◽  
Author(s):  
Cátia Teixeira ◽  
Florent Barbault ◽  
Joseph Rebehmed ◽  
Kun Liu ◽  
Lan Xie ◽  
...  
Keyword(s):  
Molecular Modeling ◽  
Pyrrole Derivatives ◽  
Modeling Studies ◽  
Molecular Modeling Studies ◽  
Hiv 1

scholarly journals Novel inhibitors of human immunodeficiency virus type 2 infectivity

2014 ◽  
Vol 95 (12) ◽  
pp. 2778-2783 ◽  
Author(s):  
Lauren B. Beach ◽  
Jonathan M. Rawson ◽  
Baek Kim ◽  
Steven E. Patterson ◽  
Louis M. Mansky
Keyword(s):  
Human Immunodeficiency Virus ◽  
Reverse Transcriptase ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Dntp Pool ◽  
Novel Drugs ◽  
Immunodeficiency Virus ◽  
Anti Hiv ◽  
Hiv 1

Human immunodeficiency virus type 2 (HIV-2) infects about two million people worldwide. HIV-2 has fewer treatment options than HIV-1, yet may evolve drug resistance more quickly. We have analysed several novel drugs for anti-HIV-2 activity. It was observed that 5-azacytidine, clofarabine, gemcitabine and resveratrol have potent anti-HIV-2 activity. The EC50 values for 5-azacytidine, clofarabine and resveratrol were found to be significantly lower with HIV-2 than with HIV-1. A time-of-addition assay was used to analyse the ability of these drugs to interfere with HIV-2 replication. Reverse transcription was the likely target for antiretroviral activity. Taken together, several novel drugs have been discovered to have activity against HIV-2. Based upon their known activities, these drugs may elicit enhanced HIV-2 mutagenesis and therefore be useful for inducing HIV-2 lethal mutagenesis. In addition, the data are consistent with HIV-2 reverse transcriptase being more sensitive than HIV-1 reverse transcriptase to dNTP pool alterations.

Molecular Modeling and Dynamics Studies of HIV-1 Kissing Loop Structures

2002 ◽  
Vol 20 (3) ◽  
pp. 397-411 ◽  
Author(s):  
Nagarajan Pattabiraman ◽  
Hugo M. Martinez ◽  
Bruce A. Shapiro
Keyword(s):  
Molecular Modeling ◽  
Hiv 1 ◽  
Kissing Loop
Sign in / Sign up

Export Citation Format

Share Document